Literature DB >> 34586889

Evaluation of MicroScan WalkAway for Determination of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility in Carbapenem-Resistant Gram-Negative Bacilli.

Carmen Antonia Sanches Ito1,2, Larissa Bail1,2, Lavinia Nery Villa Stangler Arend2,3, Kleber Oliveira Silva4, Simone Sebold Michelotto5, Keite da Silva Nogueira6,7, Felipe Francisco Tuon2.   

Abstract

We evaluated the performance of ceftazidime-avibactam and ceftolozane-tazobactam MicroScan Neg multidrug-resistant MIC 1 (NMR1) panel for clinical carbapenem-nonsusceptible Gram-negative bacilli isolates. We evaluated 212 clinically significant carbapenem-nonsusceptible Gram-negative bacilli (139 Pseudomonas aeruginosa and 73 KPC-producing Enterobacterales) from 71 Brazilian hospitals (2013 to 2020). Ceftazidime-avibactam and ceftolozane-tazobactam MICs from the panel were compared with a broth microdilution (BMD) test as the reference method. Essential agreement (EA) and categorical agreement (CA) were assessed. For P. aeruginosa, antimicrobial susceptibility testing error rates were calculated using the error-rate bound method. Discrepancies were initially observed with 11 isolates; 4 resolved after retesting, 2 in favor of the NMR1 and 2 in favor of the BMD method. The ceftazidime-avibactam EA (overall and evaluable) was 100% for P. aeruginosa and Enterobacterales. The CA was 100% for Enterobacterales and 98.6% for P. aeruginosa. The ceftolozane-tazobactam EA was 98.6% and 100% (overall and evaluable, respectively), and the CA was 96.4% for P. aeruginosa. For ceftazidime/avibactam, no very major error (VME) was found, and the major error (ME) rate was 4.2% (2/48). For ceftolozane-tazobactam and P. aeruginosa, using the CLSI breakpoints, the minor error (mE) was 11.4%, and no VME or ME was found. While using EUCAST breakpoints, the VME was 11.4% with no ME. The mE becomes ME or VME in the absence of the intermediate category. All categorical errors were also within 1 log of MIC variation, and the adjusted error rate for CLSI/EUCAST was 0% (0/212). The NMR1 panel is an option to test ceftazidime-avibactam for KPC-producing Enterobacterales and carbapenem-nonsusceptible P. aeruginosa. When a MIC of 4 mg/liter for ceftolozane-tazobactam is obtained using this method, an alert could be created, and the results could be confirmed by an alternative method.

Entities:  

Keywords:  Gram-negative bacilli; carbapenemase; ceftazidime-avibactam; ceftolozane-tazobactam; susceptibility tests

Mesh:

Substances:

Year:  2021        PMID: 34586889      PMCID: PMC8601251          DOI: 10.1128/JCM.01536-21

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  15 in total

1.  Multicenter Evaluation of Ceftazidime-Avibactam Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa on the Vitek 2 System.

Authors:  Romney Humphries; Shelley Campeau; Thomas E Davis; Kristin J Nagaro; Vincent J LaBombardi; Simone Franklin; Lisa Heimbach; Hari P Dwivedi
Journal:  J Clin Microbiol       Date:  2021-02-18       Impact factor: 5.948

2.  Performance of ceftazidime/avibactam susceptibility testing methods against clinically relevant Gram-negative organisms.

Authors:  E Wenzler; M Lee; T J Wu; K A Meyer; R K Shields; M H Nguyen; C J Clancy; R M Humphries; A T Harrington
Journal:  J Antimicrob Chemother       Date:  2019-03-01       Impact factor: 5.790

Review 3.  CLSI Methods Development and Standardization Working Group Best Practices for Evaluation of Antimicrobial Susceptibility Tests.

Authors:  Romney M Humphries; Jane Ambler; Stephanie L Mitchell; Mariana Castanheira; Tanis Dingle; Janet A Hindler; Laura Koeth; Katherine Sei
Journal:  J Clin Microbiol       Date:  2018-03-26       Impact factor: 5.948

Review 4.  Antimicrobial susceptibility testing: currently used methods and devices and the near future in clinical practice.

Authors:  M Benkova; O Soukup; J Marek
Journal:  J Appl Microbiol       Date:  2020-06-29       Impact factor: 3.772

Review 5.  New β-Lactam-β-Lactamase Inhibitor Combinations.

Authors:  Dafna Yahav; Christian G Giske; Alise Grāmatniece; Henrietta Abodakpi; Vincent H Tam; Leonard Leibovici
Journal:  Clin Microbiol Rev       Date:  2020-11-11       Impact factor: 26.132

6.  Changing Epidemiology and Decreased Mortality Associated With Carbapenem-resistant Gram-negative Bacteria, 2000-2017.

Authors:  Ahmed Babiker; Lloyd G Clarke; Melissa Saul; Julie A Gealey; Cornelius J Clancy; M Hong Nguyen; Ryan K Shields
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

Review 7.  Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.

Authors:  Felipe Francisco Tuon; Jaime L Rocha; Marcelo R Formigoni-Pinto
Journal:  Infection       Date:  2017-11-07       Impact factor: 3.553

8.  Utility of a novel multiplex TaqMan PCR assay for metallo-β-lactamase genes plus other TaqMan assays in detecting genes encoding serine carbapenemases and clinically significant extended-spectrum β-lactamases.

Authors:  Rosemary Swayne; Matthew J Ellington; Martin D Curran; Neil Woodford; Sani H Aliyu
Journal:  Int J Antimicrob Agents       Date:  2013-08-09       Impact factor: 5.283

Review 9.  Advances in Rapid Identification and Susceptibility Testing of Bacteria in the Clinical Microbiology Laboratory: Implications for Patient Care and Antimicrobial Stewardship Programs.

Authors:  Florian P Maurer; Martin Christner; Moritz Hentschke; Holger Rohde
Journal:  Infect Dis Rep       Date:  2017-03-30

10.  Evaluation of in vitro activity of ceftolozane-tazobactam against recent clinical bacterial isolates from Brazil - the EM200 study.

Authors:  Felipe Francisco Tuon; Juliette Cieslinski; Suellen da Silva Rodrigues; Fernando Brandão Serra; Marina Della-Negra de Paula
Journal:  Braz J Infect Dis       Date:  2020-04-28       Impact factor: 3.257

View more
  2 in total

1.  German Multicenter Study Analyzing Antimicrobial Activity of Ceftazidime-Avibactam of Clinical Meropenem-Resistant Pseudomonas aeruginosa Isolates Using a Commercially Available Broth Microdilution Assay.

Authors:  Jana Manzke; Raphael Stauf; Bernd Neumann; Ernst Molitor; Gunnar Hischebeth; Michaela Simon; Jonathan Jantsch; Jürgen Rödel; Sören L Becker; Alexander Halfmann; Thomas A Wichelhaus; Michael Hogardt; Annerose Serr; Christina Hess; Andreas F Wendel; Ekkehard Siegel; Holger Rohde; Stefan Zimmermann; Jörg Steinmann
Journal:  Antibiotics (Basel)       Date:  2022-04-19

Review 2.  Pathogenesis of the Pseudomonas aeruginosa Biofilm: A Review.

Authors:  Felipe Francisco Tuon; Leticia Ramos Dantas; Paula Hansen Suss; Victoria Stadler Tasca Ribeiro
Journal:  Pathogens       Date:  2022-02-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.